Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NX:xSmtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnuOo1GUUN3ME2wMlYyOjN5IN88US=> M2rRdHNCVkeHUh?=
H4 NGfafmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PIeWlEPTB;MD62OlI5KM7:TR?= MoKzV2FPT0WU
PA-1 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwOEewPVYh|ryP MljQV2FPT0WU
NKM-1 NXvvUVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG4UXpKSzVyPUGuNFQ6OzFizszN NULwdFlGW0GQR1XS
NEC8 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFwMkG1O|Ih|ryP NGT0[npUSU6JRWK=
EoL-1-cell M1vxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMk[3NFEh|ryP NGXVSIFUSU6JRWK=
K5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP2dVZnUUN3ME2xMlQzODd{IN88US=> MkfjV2FPT0WU
QIMR-WIL M4Plcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj6VpZOUUN3ME2xMlYxQDV2IN88US=> NF3pdWNUSU6JRWK=
MOLT-16 M1vKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nWc2lEPTB;MT63PFYxPCEQvF2= MlTzV2FPT0WU
CHP-212 NYDGWotpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorpTWM2OD1zLkixN|Y6KM7:TR?= NH;nU2JUSU6JRWK=
CTB-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfrTWM2OD1{LkCyNlQ3KM7:TR?= MYHTRW5ITVJ?
MOLT-4 NETwWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJwM{K4OVMh|ryP M13zXHNCVkeHUh?=
A101D M4PJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e0UGlEPTB;Mj6zOVAyKM7:TR?= M2LvfnNCVkeHUh?=
DOHH-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7lPVdvUUN3ME2yMlQzOjd7IN88US=> Mn\HV2FPT0WU
ES4 NELw[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfLTWM2OD1{LkSzNVU2KM7:TR?= M2HwS3NCVkeHUh?=
SW780 NHPEe|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV34RoRQUUN3ME2yMlUxQDh|IN88US=> NHW4N5FUSU6JRWK=
VA-ES-BJ MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDCfopUUUN3ME2yMlU1OTFizszN MX3TRW5ITVJ?
RPMI-8866 NX\YS|l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe0XmxKSzVyPUKuOVYzOTRizszN NFOzS5RUSU6JRWK=
ML-2 MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwNU[1O|Yh|ryP M4HPT3NCVkeHUh?=
MSTO-211H M2TyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7EOoVKSzVyPUKuOVc1PTFizszN M3nXbHNCVkeHUh?=
JVM-3 NYrWboFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfsdoxKSzVyPUKuOVk{OjRizszN MoTWV2FPT0WU
A3-KAW M1;lZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOyRXFKSzVyPUKuOlE5OThizszN M{XMXnNCVkeHUh?=
DK-MG MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzaeWVKSzVyPUKuOlI1PzFizszN NG\XfWJUSU6JRWK=
LNCaP-Clone-FGC NX;xeoZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJwNkSzNVgh|ryP MYfTRW5ITVJ?
HT-144 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HXUGlEPTB;Mj62OFU4PyEQvF2= M4fUNHNCVkeHUh?=
NB69 M4nxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uxfWlEPTB;Mj62OVM{PCEQvF2= NHj1O4tUSU6JRWK=
A172 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HjdWlEPTB;Mj62O|U5QCEQvF2= M2mzWXNCVkeHUh?=
RS4-11 NF;zPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fsfWlEPTB;Mj63NlQxPyEQvF2= NHPwXFBUSU6JRWK=
DU-4475 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHjTWM2OD1{Lke5OVAzKM7:TR?= NHLEfYpUSU6JRWK=
SJSA-1 M3rqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DxSWlEPTB;Mj64NlU2PiEQvF2= MUPTRW5ITVJ?
BV-173 NXfpOHE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG5bYROUUN3ME2yMlg1PDN7IN88US=> NHn6codUSU6JRWK=
U-2-OS NGjpT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofSTWM2OD1{LkmxNFch|ryP MknsV2FPT0WU
CHP-134 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\wO3FKSzVyPUKuPVM5QDJizszN MX\TRW5ITVJ?
D-502MG NF\GdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7sdWZlUUN3ME2yMlk4OTV2IN88US=> M37hcHNCVkeHUh?=
KS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTW[mJKSzVyPUOuNFE3OjNizszN NVLjbYVrW0GQR1XS
A204 M1HGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe3cmVKSzVyPUOuNFU2QDhizszN M{HwV3NCVkeHUh?=
KGN NHvXe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGntWZFKSzVyPUOuNFg1QTZizszN NIjPWFRUSU6JRWK=
NCI-H292 MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoflTWM2OD1|LkGyNFI5KM7:TR?= M3PKbXNCVkeHUh?=
CAKI-1 NGXSZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfqPGJuUUN3ME2zMlEzPjl2IN88US=> NXnxbVBIW0GQR1XS
C2BBe1 NF;z[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrTZnFtUUN3ME2zMlE4ODJ4IN88US=> MUTTRW5ITVJ?
NB10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;5O2lEPTB;Mz6yNFk3PiEQvF2= MoS5V2FPT0WU
MHH-NB-11 NW\RToNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPTTWM2OD1|LkK2PFI4KM7:TR?= MXrTRW5ITVJ?
NCI-SNU-1 NYOx[mY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfvOHJpUUN3ME2zMlI4QDR|IN88US=> M1\WbXNCVkeHUh?=
HCT-116 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXlOoZuUUN3ME2zMlMxOzN3IN88US=> M4LkR3NCVkeHUh?=
G-401 NYPZ[FhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jtR2lEPTB;Mz6zOlMzOiEQvF2= MmWyV2FPT0WU
MN-60 NIfPVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\5VJdKSzVyPUOuOFQxQTJizszN NUHjV3p[W0GQR1XS
SW982 NU\QfXFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwNUC4OFgh|ryP Ml;uV2FPT0WU
RKO MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXCNm9KSzVyPUOuOVM6OzZizszN NF20UplUSU6JRWK=
D-283MED NVXJT|BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qwcGlEPTB;Mz61O|k5PiEQvF2= MYHTRW5ITVJ?
LB996-RCC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOzdoJiUUN3ME2zMlYzPTV6IN88US=> MnTRV2FPT0WU
A549 M3LVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLuTWM2OD1|Lk[zOVUzKM7:TR?= NIPEPW1USU6JRWK=
LB2241-RCC NFLZVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTNwNkW3NFgh|ryP NXXRXVNyW0GQR1XS
SK-HEP-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPLS|BKSzVyPUOuO|QzQTdizszN Mk\1V2FPT0WU
G-402 NHy0cZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNwOEC4N|Ih|ryP MofYV2FPT0WU
GOTO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\1coJMUUN3ME2zMlg1OzN|IN88US=> NInQNnVUSU6JRWK=
LOXIMVI MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvHTGpKSzVyPUOuPFU3PzVizszN MXvTRW5ITVJ?
NH-12 M{\Ddmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTRwMEG5OVkh|ryP NGfDenFUSU6JRWK=
CTV-1 NXn0VmQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e5dWlEPTB;ND6wO|k4OyEQvF2= NFfsSFNUSU6JRWK=
CP50-MEL-B NUmydWNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPHTWM2OD12LkK0N|kzKM7:TR?= M3rrTXNCVkeHUh?=
RH-18 NGnueZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\xWFdKSzVyPUSuNlc4ODZizszN NVzvbnRYW0GQR1XS
NB17 MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml33TWM2OD12LkOxO|Y5KM7:TR?= NWXPOY82W0GQR1XS
A375 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKxXnRKSzVyPUSuN|M2OjRizszN M{DUfHNCVkeHUh?=
IST-MES1 M3rUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnCTJFKSzVyPUSuOFE1OTFizszN MnW5V2FPT0WU
MZ2-MEL MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwNUCxOVUh|ryP MlPpV2FPT0WU
CAL-54 NF[2e2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3xNm5KSzVyPUSuOVMxOTlizszN MUXTRW5ITVJ?
NCI-H28 M{\weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwNkK3NVch|ryP NWPXUJhxW0GQR1XS
D-247MG NXroZ2FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L2[mlEPTB;ND63OVA4OiEQvF2= NH\RXmtUSU6JRWK=
NCI-H460 NETPRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LKfWlEPTB;ND65NVEzPyEQvF2= NXnZeVN2W0GQR1XS
MCF7 NYq3WItIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljMTWM2OD13LkS0NlQ1KM7:TR?= Ml\TV2FPT0WU
697 NWO3b5E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17ySmlEPTB;NT60OFU2KM7:TR?= NFTlb4hUSU6JRWK=
ONS-76 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjpcI1KSzVyPUWuOVcxODlizszN MoP3V2FPT0WU
C32 NUHZWZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTVwNkCwNlkh|ryP MW\TRW5ITVJ?
OS-RC-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2yTWM2OD13LkezPFg4KM7:TR?= Mn34V2FPT0WU
MEL-HO NFrrUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj2VWtLUUN3ME21Mlg2PjZ5IN88US=> NYTlT4R[W0GQR1XS
LoVo NWfX[VJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHntepFKSzVyPU[uNFE3OjRizszN M4XEc3NCVkeHUh?=
AGS Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZwMUS4Nlgh|ryP M4HLVnNCVkeHUh?=
GI-ME-N M33SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLhXnZFUUN3ME22MlIzPDJzIN88US=> MWjTRW5ITVJ?
H-EMC-SS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nDN2lEPTB;Nj6zPFYh|ryP MXjTRW5ITVJ?
RVH-421 NH60[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TkW2lEPTB;Nj60NlQzQCEQvF2= M3f0UXNCVkeHUh?=
SW954 MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTZwNUW1O|Ih|ryP MoDZV2FPT0WU
NB5 M3W3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jUTmlEPTB;Nj61OlE5OyEQvF2= M4[4ZnNCVkeHUh?=
NCI-H2122 NFfzS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjzbYhKSzVyPU[uOVg4QTNizszN NXPMNotnW0GQR1XS
AM-38 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe5U4lKSzVyPU[uO|U3OzlizszN NHXZN5VUSU6JRWK=
KNS-81-FD NVXXZmdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHqSYF3UUN3ME22Mlc3PDl2IN88US=> NVHBU2lHW0GQR1XS
LS-513 M4jiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjyVYhKSzVyPU[uO|kxOjZizszN NXzVWWl3W0GQR1XS
A427 NFzOTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXuTWM2OD14Lki3PFI6KM7:TR?= NFLLcJZUSU6JRWK=
WM-115 M2nPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m4e2lEPTB;Nj65N|I{KM7:TR?= NFLxe4lUSU6JRWK=
COLO-829 NHq1WpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTdwMkSxPFgh|ryP MXTTRW5ITVJ?
NCI-H1650 M{f3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTdwM{myNlgh|ryP MYjTRW5ITVJ?
NCI-H358 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLkTWM2OD15LkS0PFc6KM7:TR?= MlXSV2FPT0WU
HT-1080 M1:zbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTdwNEiyOVQh|ryP M1zCbHNCVkeHUh?=
HCC2218 M3TpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTdwNkK5O{DPxE1? MknSV2FPT0WU
NCI-H661 NEjDZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zLZmlEPTB;Nz64O|A3QSEQvF2= MX3TRW5ITVJ?
KM-H2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn3TWM2OD15Lki4Olk1KM7:TR?= NXrlSHhXW0GQR1XS
RPMI-2650 NFvWfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjDTFREUUN3ME23Mlk1PDF2IN88US=> NF3reHhUSU6JRWK=
NCI-H226 MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLqTWM2OD16LkKxNVIzKM7:TR?= NWDvfXRnW0GQR1XS
MKN45 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRThwMk[2NFIh|ryP MXTTRW5ITVJ?
D-392MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLxTWM2OD16LkWyO|IzKM7:TR?= MVPTRW5ITVJ?
RCC10RGB M1;FWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLyTWM2OD16Lki2Olk2KM7:TR?= MXPTRW5ITVJ?
CAL-51 M{C0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImwXpdKSzVyPUmuNVAzPTFizszN MnS0V2FPT0WU
COLO-678 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTlwM{K4NVEh|ryP NE\odmdUSU6JRWK=
SK-MEL-24 MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTlwNUW4OVYh|ryP MVHTRW5ITVJ?
SK-MEL-30 M1;qUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q0emlEPTB;OT65OFQ4PiEQvF2= NEe3dYRUSU6JRWK=
MMAC-SF NFrXZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLDNZdKSzVyPUGwMlM6PjFizszN M2DvXHNCVkeHUh?=
NTERA-S-cl-D1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;BU3NKSzVyPUGwMlY2ODhizszN NFrtRVBUSU6JRWK=
NB12 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XWTWlEPTB;MUGuOVA{KM7:TR?= NXXueWo6W0GQR1XS
UACC-257 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;JV2lEPTB;MUGuPFY6PSEQvF2= M{LC[HNCVkeHUh?=
LAN-6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXBT4ZKSzVyPUGxMlk6OjhizszN NXTKeolyW0GQR1XS
SW1573 MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjuTWM2OD1zMj6zNFg3KM7:TR?= NVrtZm1[W0GQR1XS
NMC-G1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS4R2hKSzVyPUGyMlQyPzVizszN NX;oNHlUW0GQR1XS
SHP-77 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTUTWM2OD1zMj61OVc1KM7:TR?= NWi1blZxW0GQR1XS
IGROV-1 NH;sVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHRPIZMUUN3ME2xNk43PTd|IN88US=> MX\TRW5ITVJ?
22RV1 M1n6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7tRlBnUUN3ME2xNk45ODV7IN88US=> MWrTRW5ITVJ?
SK-MEL-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3yTWM2OD1zMz6zPVc{KM7:TR?= MljCV2FPT0WU
NCI-H1563 M1OyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIizfY5KSzVyPUGzMlQzODJizszN MkTDV2FPT0WU
IGR-1 NELXNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF2LkCzOFch|ryP M2LUSXNCVkeHUh?=
EW-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XnNmlEPTB;MUSuNVY{QSEQvF2= M{TnbnNCVkeHUh?=
JEG-3 NVP6OXY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nDT2lEPTB;MUSuOFk2OyEQvF2= M1zKe3NCVkeHUh?=
ES3 NHLmeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF2Lk[1OlIh|ryP NWO4b4J[W0GQR1XS
MDA-MB-175-VII MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TJfmlEPTB;MUSuO|EyOSEQvF2= Mmi0V2FPT0WU
P30-OHK NHG3W2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzFSWt2UUN3ME2xOU4xPDl4IN88US=> NF71VHZUSU6JRWK=
GP5d NYH1R5FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF3LkG0OlYh|ryP NULE[JhZW0GQR1XS
HMV-II MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPGT4ZxUUN3ME2xOU4{OzN|IN88US=> MVzTRW5ITVJ?
COLO-679 M2W2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXrXXJRUUN3ME2xOU42ODFizszN NI[ybHNUSU6JRWK=
JAR NFm0c|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\5UWlEPTB;MUWuO|IxPSEQvF2= Mor4V2FPT0WU
NCI-H1666 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnyc3RWUUN3ME2xOU46Ozl7IN88US=> M13LfXNCVkeHUh?=
SW48 M{D4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG4b3pKSzVyPUG1Mlk2OTZizszN NFO3UnNUSU6JRWK=
NCI-H720 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF3Lkm5PFkh|ryP MX;TRW5ITVJ?
HT-1197 NFrtdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDL[25KSzVyPUG2MlA{PTJizszN MmGwV2FPT0WU
HL-60 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF4LkCzPFQh|ryP NE\B[4NUSU6JRWK=
BEN NEj3TpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLUTWM2OD1zNj61OlM5KM7:TR?= MVXTRW5ITVJ?
HAL-01 MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL4TWM2OD1zNj64PVA6KM7:TR?= NEiwV4tUSU6JRWK=
SW900 NWT4RmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF4LkmxN|Ih|ryP MnvjV2FPT0WU
SBC-1 NUTscoNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M133NmlEPTB;MUeuOVQzQSEQvF2= NIntd3JUSU6JRWK=
SH-4 M{XiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojGTWM2OD1zNz61PFQyKM7:TR?= MWjTRW5ITVJ?
UACC-62 NHXJWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHuOpdKSzVyPUG3Mlc3OzdizszN NFf4N2tUSU6JRWK=
BHT-101 M3GybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHYfI5LUUN3ME2xPU45PzB3IN88US=> NV7KXG17W0GQR1XS
DB NF3UWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnGTWM2OD1{MT61OlQ6KM7:TR?= MVHTRW5ITVJ?
SK-MEL-1 NV7QcXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC5TWM2OD1{MT61PFczKM7:TR?= MnG0V2FPT0WU
NCI-H747 NIL2WXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHvfodKSzVyPUKyMlc{PzlizszN MXPTRW5ITVJ?
SK-LU-1 M1vFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;PS5hqUUN3ME2yN{4{PTJ2IN88US=> NFmyNFlUSU6JRWK=
KG-1 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XyeWlEPTB;MkOuOFk1PiEQvF2= NFfJOnlUSU6JRWK=
LXF-289 MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmzT29jUUN3ME2yN{44OTRizszN NFW5OJJUSU6JRWK=
HCC1954 NV3EPJpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\KbmlEPTB;MkSuPFg1PCEQvF2= MWjTRW5ITVJ?
Ramos-2G6-4C10 NUew[HV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vHR2lEPTB;Mk[uOFk5OSEQvF2= NVi4cmgyW0GQR1XS
DBTRG-05MG NG\2N2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofZTWM2OD1{Nj62OFg5KM7:TR?= MXXTRW5ITVJ?
NCI-H2052 NUDleJVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXPTWM2OD1{Nz61Olg1KM7:TR?= MXPTRW5ITVJ?
RMG-I MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ7LkSxN|kh|ryP MknhV2FPT0WU
H9 NWDqWppvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNzLkOwNFgh|ryP NIGwc5VUSU6JRWK=
GR-ST NGTTeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN{LkS0OVMh|ryP NXHDSoExW0GQR1XS
Mo-T M4HWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH6TWM2OD1|Mj61NFQ3KM7:TR?= NGnyPVVUSU6JRWK=
SW1088 NIHz[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPsVJc1UUN3ME2zNk46QDBzIN88US=> MlLzV2FPT0WU
LB2518-MEL NVfaWVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjkV4hkUUN3ME2zN{4xPzl5IN88US=> NYHsWIhMW0GQR1XS
NCI-H82 NVvDcnpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX6dIxvUUN3ME2zN{4yPjZzIN88US=> M13ObXNCVkeHUh?=
LAMA-84 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrRe5RKSzVyPUO0MlYxPzNizszN MojCV2FPT0WU
KYSE-450 NV\Wc29zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN2Lk[3O|Yh|ryP MmDmV2FPT0WU
LU-99A NFv2bmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfHUGtKSzVyPUO1MlAxODdizszN NGPVPVVUSU6JRWK=
BE-13 MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nGdWlEPTB;M{WuOlU1PSEQvF2= MYHTRW5ITVJ?
GAK MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN3Lk[5OUDPxE1? MUDTRW5ITVJ?
NCI-H1573 NUH3cGNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHrbllqUUN3ME2zOU45QDF6IN88US=> MUDTRW5ITVJ?
AsPC-1 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLDTWM2OD1|Nj6xOVI4KM7:TR?= MWrTRW5ITVJ?
HDLM-2 NUnvfXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHiTWM2OD1|Nj6zNVYh|ryP NXjOV|BoW0GQR1XS
NCI-H441 M3rXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly0TWM2OD1|Nz6wOlkyKM7:TR?= M1PRdHNCVkeHUh?=
CAL-27 NG\5UXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;VWpNFUUN3ME2zO{44OjNzIN88US=> MYXTRW5ITVJ?
OVCAR-3 M3;pVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTN7LkOxPFEh|ryP MofuV2FPT0WU
RPMI-8226 NUjDOlAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN7LkW5PEDPxE1? M{HmVXNCVkeHUh?=
EFO-21 NXPNPWdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LHOmlEPTB;NECuOVgyPCEQvF2= NV3vU|lZW0GQR1XS
SNU-C2B Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPKVnZsUUN3ME20NU42ODh2IN88US=> NF:wPIxUSU6JRWK=
VM-CUB-1 NV3MZoNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;2[mFKSzVyPUSzMlgxOzdizszN NEWxPFNUSU6JRWK=
NCI-H2087 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\ZZnBKSzVyPUS1MlAzOzNizszN M4\GVnNCVkeHUh?=
EW-16 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTkdpNKSzVyPUS2MlMyOzdizszN MljpV2FPT0WU
SK-N-AS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTR4LkexOlch|ryP Mln3V2FPT0WU
COR-L105 NEm3UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTR4Lki4OVch|ryP MoLRV2FPT0WU
DEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH64VJRKSzVyPUS4MlA1OjlizszN NFP3cHJUSU6JRWK=
JVM-2 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vaPWlEPTB;NEiuNFU2QCEQvF2= M1P5VnNCVkeHUh?=
KARPAS-45 NXjqT|ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf0VpZKSzVyPUS5MlQ2OzhizszN M{jOVHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID